Petrovax Pharm gets new director for its production complex
Moscow, March 2025. Petrovax Pharm, a Russian biotechnology company, announces changes in top management. Regina Ibragimova takes charge of the production complex in Podolsk as its director. Her appointment marks an important step in corporate development and future biotech projects.
Regina Ibragimova joined Petrovax Pharm in 2021 as its Chief Process Engineer; in 2024, she was appointed Production Director and in 2025, the director of the plant. Mrs. Ibragimova was now tasked with fulfilling strategic objectives of expanding the full-cycle manufacturing facilities (including those involved in substance production) and increasing the output of highly-sought vaccines and biotech products.
Key areas of interest include the full-cycle localization of Areima® (camrelizumab), an immuno-oncology drug used in nasopharyngeal and esophageal cancer therapy authorized in Russia in 2024. Another significant project is the production of the orphan drug Fabagal® employed to treat the rare genetic Fabry disease. Last year, the company partnered with N.F. Gamaleya NCEM to complete the full transfer of the drug production technology, including substance biosynthesis, in record time.
says Regina Ibragimova, the new director of the Petrovax Pharm plant. "This is a strong and ambitious biotech project, which we managed to realize in a short period of time, and we are really proud of it. New drugs we plan to introduce to the market will require expanded production capacities and automated business processes. Our biotechnological complex that we will use to manufacture substances and genetically engineered drugs for the Russian market and exports is nearing completion".
Regina Ibragimova graduated from Bashkir State University with a degree in Chemistry and Chemical Technology and continued her advanced training studies at Sechenov University as a specialist responsible for the production, quality and labeling of drugs. She started her career in the pharmaceutical industry as a technologist at Pharmstandard, and four years later, she participated in the launch of a new pharmaceutical production facility in Kazan as a leading process engineer. Once the project was successfully completed, she was promoted to a chief process engineer.
Regina Ibragimova significantly changed the team structure and optimized processes in a similar position at Petrovax Pharm in just three years. Currently, she leads the Petrovax production complex in the Moscow Region, which includes four production lines, biochemical, control and analytical, microbiological laboratories, engineering systems and a pharmaceutical warehouse.
Reference information
Petrovax Pharm is a Russian company of novel biopharmaceutical practices, actively investing in scientific research and development. Its portfolio includes original drugs, biosimilars and branded generic products. The in-house R&D center for pre-clinical studies enables a full cycle of drug development. Petrovax has set up its development strategy aiming to provide patients with highly-sought vaccines and drugs used to prevent and treat infectious, oncological and orphan diseases. The modern full-cycle production complex has enough capacity to manufacture more than 160 million doses of drugs per year. The complex is compliant with GMP standards in force in the EAEU and the EU. Manufacturing sites produce sterile and non-sterile medicines in disposable syringes, ampoules, vials in liquid, semi-solid and solid dosage forms. The facility also makes original drugs developed in-house: Polyoxidonium® and Longidaza®, Grippol® plus and Grippol® Quadrivalent influenza vaccines and localized medicines: Prevenar® 13 pneumococcal vaccine and Fabagal® orphan drug. Petrovax Pharm is implementing international technology transfer projects intended to produce high-tech drugs in cooperation with leading pharmaceutical companies: Pfizer, Abbott, ISU ABXIS and Adimmune. The company is one of the largest Russian exporters of original medicines and vaccines to the EAEU and the EU countries.
